ProtAffin Biotechnologie AG
This article was originally published in Start Up
Executive Summary
ProtAffin Biotechnologie AG's technology is based on the interactions between pro-inflammatory proteins such as chemokines, and leucocytes and endothelial cells that drive many acute and chronic inflammatory processes such as ischemia/reperfusion injury and rheumatoid arthritis. The company's CellJammer platform uses structural bioinformatics and rational protein engineering to take a target protein agonist that naturally binds to a GAG ligand and to create an antagonist that binds with higher affinity and blocks the target protein-GAG interaction.